Alterações moleculares em síndrome mielodisplásica
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S1516-84842006000300007 http://repositorio.unifesp.br/handle/11600/3229 |
Resumo: | Myelodysplastic syndrome (MDS) is a heterogenous group of clonal hematopoietic disorders. Chromosomal abnormalities detected in this disease were the start to many studies in order to characterize molecular pathogenesis. The loss of genetic material observed in most patients with MDS leads to the hypothesis of tumor suppressor genes (TSG), but this theory does not explain the initial event that underlies growth advantage of hematopoietic progenitor cells, though, different mechanisms are involved such as oncogene activation, altered signaling components and transcription factors. Oncogene mutations, such as RAS, P53, PDGF, FLT3 and MLL, for instance, may contribute to the development of MDS. Tandem mutation of FLT3 is a genetic event that occurs late in the course of the disease and these patients tend to present unfavorable prognosis and imminent transformation into acute myeloid leukemia. Quantitative as well as qualitative abnormalities of transcription factors are detected in MDS and induce the unbalance or block in the differentiation of hematopoietic cells, that results in ineffective hematopoiesis. Epigenentic alterations are characterized by DNA methylation that exerts a role in controlling genic expression. Hypermethylation and inactivation of regulating genes act in the development of the disease. There is a high risk of MDS when p15INK4B is inactivated due to hypermethylation of its promoter. Telomere shortening correlates with complex karyotypes indicating genomic instability and poor prognosis. |
id |
UFSP_604de66c60072e204a6262c058b69354 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/3229 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Alterações moleculares em síndrome mielodisplásicaMolecular abnormalities in myelodysplastic syndromeChromosomemyelodysplasic syndromeFISHPCRprognosisFLT3LOHSíndrome mielodisplásicaprognósticoFISHFLT3LOHMyelodysplastic syndrome (MDS) is a heterogenous group of clonal hematopoietic disorders. Chromosomal abnormalities detected in this disease were the start to many studies in order to characterize molecular pathogenesis. The loss of genetic material observed in most patients with MDS leads to the hypothesis of tumor suppressor genes (TSG), but this theory does not explain the initial event that underlies growth advantage of hematopoietic progenitor cells, though, different mechanisms are involved such as oncogene activation, altered signaling components and transcription factors. Oncogene mutations, such as RAS, P53, PDGF, FLT3 and MLL, for instance, may contribute to the development of MDS. Tandem mutation of FLT3 is a genetic event that occurs late in the course of the disease and these patients tend to present unfavorable prognosis and imminent transformation into acute myeloid leukemia. Quantitative as well as qualitative abnormalities of transcription factors are detected in MDS and induce the unbalance or block in the differentiation of hematopoietic cells, that results in ineffective hematopoiesis. Epigenentic alterations are characterized by DNA methylation that exerts a role in controlling genic expression. Hypermethylation and inactivation of regulating genes act in the development of the disease. There is a high risk of MDS when p15INK4B is inactivated due to hypermethylation of its promoter. Telomere shortening correlates with complex karyotypes indicating genomic instability and poor prognosis.A síndrome mielodisplásica (SMD) representa um grupo heterogêneo de doenças hematopoéticas clonais. As alterações cromossômicas observadas em SMD foram o ponto de partida para uma série de estudos para a caracterização da patogênese molecular nessa doença. A perda de material genético leva à hipótese de inativação de genes supressores tumorais (GST), mas essa teoria não explica o evento inicial desencadeador da vantagem de crescimento das células progenitoras hematopoéticas, estando outros mecanismos envolvidos, dos quais sobressaem a ativação de oncogenes, alteração de vias de sinalização e fatores de transcrição. Mutações de oncogenes, como RAS, P53, PDGF, FLT3 e MLL, dentre outros, podem contribuir para o desenvolvimento da SMD. A mutação em tandem do FLT3 é evento genético tardio no curso da doença e os pacientes portadores da mesma tendem a apresentar prognóstico desfavorável e transformação iminente para leucemia aguda. Tanto aberrações qualitativas como quantitativas de fatores de transcrição induzem o desequilíbrio ou bloqueio de diferenciação da célula hematopoética, que, por sua vez, se traduz em hematopoese ineficaz. Alterações epigenéticas são caracterizadas por metilação de DNA que tem papel no controle da expressão gênica. Hipermetilação e inativação de genes reguladores exercem função no desenvolvimento da doença. SMD de alto risco está associada à elevada prevalência de inativação do gene supressor tumoral p15INK4B por hipermetilação do promotor. Encurtamento do telômero correlaciona-se a cariótipos complexos, indicando instabilidade genômica e pior prognóstico.UNIFESP-EPM Disciplina de HematologiaFleury-Centro de Medicina DiagnósticaUNIFESP, EPM, Disciplina de HematologiaSciELOAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularUniversidade Federal de São Paulo (UNIFESP)Fleury-Centro de Medicina DiagnósticaChauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]2015-06-14T13:36:25Z2015-06-14T13:36:25Z2006-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion188-193application/pdfhttp://dx.doi.org/10.1590/S1516-84842006000300007Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 28, n. 3, p. 188-193, 2006.10.1590/S1516-84842006000300007S1516-84842006000300007.pdf1516-8484S1516-84842006000300007http://repositorio.unifesp.br/handle/11600/3229porRevista Brasileira de Hematologia e Hemoterapiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-30T01:54:26Zoai:repositorio.unifesp.br/:11600/3229Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-30T01:54:26Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Alterações moleculares em síndrome mielodisplásica Molecular abnormalities in myelodysplastic syndrome |
title |
Alterações moleculares em síndrome mielodisplásica |
spellingShingle |
Alterações moleculares em síndrome mielodisplásica Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP] Chromosome myelodysplasic syndrome FISH PCR prognosis FLT3 LOH Síndrome mielodisplásica prognóstico FISH FLT3 LOH |
title_short |
Alterações moleculares em síndrome mielodisplásica |
title_full |
Alterações moleculares em síndrome mielodisplásica |
title_fullStr |
Alterações moleculares em síndrome mielodisplásica |
title_full_unstemmed |
Alterações moleculares em síndrome mielodisplásica |
title_sort |
Alterações moleculares em síndrome mielodisplásica |
author |
Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP] |
author_facet |
Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP] |
author_role |
author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Fleury-Centro de Medicina Diagnóstica |
dc.contributor.author.fl_str_mv |
Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP] |
dc.subject.por.fl_str_mv |
Chromosome myelodysplasic syndrome FISH PCR prognosis FLT3 LOH Síndrome mielodisplásica prognóstico FISH FLT3 LOH |
topic |
Chromosome myelodysplasic syndrome FISH PCR prognosis FLT3 LOH Síndrome mielodisplásica prognóstico FISH FLT3 LOH |
description |
Myelodysplastic syndrome (MDS) is a heterogenous group of clonal hematopoietic disorders. Chromosomal abnormalities detected in this disease were the start to many studies in order to characterize molecular pathogenesis. The loss of genetic material observed in most patients with MDS leads to the hypothesis of tumor suppressor genes (TSG), but this theory does not explain the initial event that underlies growth advantage of hematopoietic progenitor cells, though, different mechanisms are involved such as oncogene activation, altered signaling components and transcription factors. Oncogene mutations, such as RAS, P53, PDGF, FLT3 and MLL, for instance, may contribute to the development of MDS. Tandem mutation of FLT3 is a genetic event that occurs late in the course of the disease and these patients tend to present unfavorable prognosis and imminent transformation into acute myeloid leukemia. Quantitative as well as qualitative abnormalities of transcription factors are detected in MDS and induce the unbalance or block in the differentiation of hematopoietic cells, that results in ineffective hematopoiesis. Epigenentic alterations are characterized by DNA methylation that exerts a role in controlling genic expression. Hypermethylation and inactivation of regulating genes act in the development of the disease. There is a high risk of MDS when p15INK4B is inactivated due to hypermethylation of its promoter. Telomere shortening correlates with complex karyotypes indicating genomic instability and poor prognosis. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-09-01 2015-06-14T13:36:25Z 2015-06-14T13:36:25Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S1516-84842006000300007 Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 28, n. 3, p. 188-193, 2006. 10.1590/S1516-84842006000300007 S1516-84842006000300007.pdf 1516-8484 S1516-84842006000300007 http://repositorio.unifesp.br/handle/11600/3229 |
url |
http://dx.doi.org/10.1590/S1516-84842006000300007 http://repositorio.unifesp.br/handle/11600/3229 |
identifier_str_mv |
Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 28, n. 3, p. 188-193, 2006. 10.1590/S1516-84842006000300007 S1516-84842006000300007.pdf 1516-8484 S1516-84842006000300007 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
188-193 application/pdf |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268421486936064 |